VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics Dec 14, 2016
VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate Development and Investor Relations Oct 4, 2016
VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer Jun 20, 2016
VistaGen Therapeutics Bolsters Clinical and Regulatory Advisory Board with Appointments of Distinguished Key Opinion Leaders in Depression Mar 22, 2016
